On 30 January, Calithera Biosciences, Inc. (NASDAQ:CALA), announced the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development. He joins the company following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKline (GSK) and Merck. At Calithera, Dr. Orford will be responsible for clinical development of CB-839, its lead oral product candidate in tumor metabolism, as well as subsequent clinical development programs. On Monday shares of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $18.18. Company’s EPS growth for next 5 years is recorded as 75.00%.
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), announced that the Company is scheduled to present a corporate overview at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. Eastern Time. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) in last trading activity increased 15.26% to close at $5.59. Company weekly performance is 11.80% while its quarterly performance stands at 16.46%. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) is -67.87% away from its 52 week high.
Coherus BioSciences, Inc. (NASDAQ:CHRS), announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. On last trading day Coherus Biosciences, Inc. (NASDAQ:CHRS) increased 12.91% to close at $32.36. Its volatility for the week is 14.21% while volatility for the month is 10.09%. CHRS’s EPS growth for past 5 years was -44.33%. Coherus Biosciences, Inc. (NASDAQ:CHRS) monthly performance is 51.78%.
Trevena, Inc. (NASDAQ: TRVN), announced positive data from a Phase 1 multiple ascending dose study of TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. Trevena, Inc. (NASDAQ:TRVN) has 1.50% insider ownership while its institutional ownership stands at 76.40%. In last trading activity company’s stock closed at $5.35.
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced its acquisition of Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. On last trading day Cellular Biomedicine Group Inc. (NASDAQ:CBMG) increased 10.85% to close at $23.40. Its volatility for the week is 10.87% while volatility for the month is 8.60%. CBMG’s EPS growth for past 5 years was -19.20%. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) monthly performance is 55.90%.